Agomelatine is a melatonin MT1/2 receptor activator that also inhibits 5-HT2C receptors. Agomelatine displays antidepressant, anxiolytic, and hypnotic characteristics and is currently being examined as a marketable antidepressant. Agomelatine improves sleep quality and efficacy and treats insomnia. This compound also enhances neuroplasticity and neurogenesis in the hippocampus and prefrontal cortex.
| Cas No. | 138112-76-2 |
|---|---|
| Purity | ≥98% |
| Formula | C15H17NO2 |
| Formula Wt. | 243.30 |
| IUPAC Name | N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | A2658 MSDS PDF |
|---|---|
| Info Sheet | A2658 Info Sheet PDF |
Smeraldi E, Delmonte D. Agomelatine in depression. Expert Opin Drug Saf. 2013 Nov;12(6):873-80. PMID: 24033095.
Pompili M, Serafini G, Innamorati M, et al. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: a critical review. World J Biol Psychiatry. 2013 Aug;14(6):412-31. PMID: 23530731.
Srinivasan V, Zakaria R, Othaman Z, et al. Melatonergic drugs for therapeutic use in insomnia and sleep disturbances of mood disorders. CNS Neurol Disord Drug Targets. 2012 Mar;11(2):180-9. PMID: 22483286.
Bertaina-Anglade V, la Rochelle CD, Boyer PA, et al. Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol. 2006 Dec;17(8):703-13. PMID: 17110796.
Papp M, Litwa E, Gruca P, et al. Anxiolytic-like activity of agomelatine and melatonin in three animal models of anxiety. Behav Pharmacol. 2006 Feb;17(1):9-18. PMID: 16377959.
